Sage Therapeutics, Inc.
SAGE
$6.69
-$0.065-0.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 42.65% | -192.85% | 53.60% | 35.85% | 26.12% |
| Total Depreciation and Amortization | -66.67% | -68.46% | -22.73% | -6.04% | 4.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -52.07% | -56.30% | -48.99% | 108.24% | -27.98% |
| Change in Net Operating Assets | -143.71% | 119.53% | -102.83% | -67.06% | 342.40% |
| Cash from Operations | -116.03% | 44.31% | 39.38% | 38.84% | 75.38% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -67.17% | 11.03% | -49.57% | -100.84% | -28.53% |
| Cash from Investing | -67.17% | 10.73% | -49.47% | -100.85% | -28.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -84.48% | -- | -48.23% | 857.78% | -52.77% |
| Repurchase of Common Stock | -4,600.00% | 99.24% | -9,875.00% | 87.50% | 99.68% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -90.49% | 99.24% | -62.56% | 852.89% | -41.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -134.70% | 74.28% | -101.00% | 14.49% | 135.22% |